Drug intelligence / Profile preview

MS013

Development stage: Preclinical
Lead developer: Hangzhou Medimscience Biomedical Technology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MS013 is a preclinical-stage monoclonal antibody developed by Medimscience for the treatment of solid tumors. It specifically targets MT013, a proprietary macrophage-related protein within the tumor microenvironment. By targeting MT013, the antibody aims to modulate macrophage activity, potentially overcoming immune suppression and enhancing anti-tumor immune responses. The program is currently in the preclinical phase of development, focusing on its potential to reprogram the immune microenvironment in various solid tumor types.

Other names: MT013 monoclonal antibodyMT-013 monoclonal antibodyMT 013 monoclonal antibody

Targets

NFKB1 (NF-κB1)

Beyond the preview

Go deeper on MS013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MS013.

Explore the full profile